AzTrials
AzTrials

Knee Joint ArthritisPhase 4NCT01503528

Motor Sparing Block vs. Peri-Articular Catheters

A Phase 4 study testing Motor Sparing Nerve Block and Peri-articular Catheters in people with Knee Joint Arthritis and Knee Joint Arthroplasty, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study is designed to determine if one anaesthetic modality, either motor sparing nerve block or peri-articular local infiltration anaesthesia with infusion, is superior in providing postoperative analgesia following total knee joint arthroplasty and if the efficacy of analgesia affects TKA outcomes. Read more about this study

Who is it for?
Ages 30 to 100 years
Conditions the study is for
Knee Joint Arthritis, Knee Joint Arthroplasty
What is being tested?
Motor Sparing Nerve Block and Peri-articular Catheters
Could I receive a placebo?
No, everyone receives an active treatment
How many people
54 participants
Where
1 siteCanada
Study dates
16 Oct 2017to 10 Sep 2018
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients ASA physical status 1-3, Ability to give informed consent, No contraindications to regional techniques, Ability to perform study related tests, Scheduled for primary unilateral total knee arthroplasty

Who cannot join

  • Revision of arthroplasty, Allergy to local anesthetics and multimodal analgesic drugs, Contraindications to spinal anesthesia, Inability to perform study related procedures, Inability to give informed consent, Wheel chair bound, Pregnancy, Chronic renal failure, BMI >45

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • London Health Sciences Centre University Hospital

    London, Ontario

Other trials in Canada

About this study

Official title: Outcomes After Total Knee Joint Arthroplasty: A Comparative Study Using 3 Different Analgesic Techniques

This study is designed to determine if one anaesthetic modality, either motor sparing nerve block or peri-articular local infiltration anaesthesia with infusion, is superior in providing postoperative analgesia following total knee joint arthroplasty and if the efficacy of analgesia affects TKA outcomes. These outcomes include pain and function for a period of up to 3 months, narcotic consumption, and specific non-pain complications, including cardiac, respiratory, central nervous system, thromboembolism, infection, nausea and vomiting and urinary retention.

Economic outcomes will also be examined, including length of hospital stay, direct health care costs and patient satisfaction.

Read the detailed description

Seventy patients of either sex with ASA physical status of 1-3, aged greater than 30 years scheduled for elective primary unilateral total knee arthroplasty will be the randomized to one of 2 groups. The patients will be identified by the surgeons and seen in the pre-admit clinic to obtain informed consent, and collect health and joint related data using SF-12, Knee Society Scores, and WOMAC surveys. The randomization will occur in the pre-admit clinic with a closed envelope system. This is not a blinded study for logistical reasons.

Group 1: Control- Motor Sparing Nerve Block Continuous Motor sparing knee block (using 60mL of 0.5% Ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room by anesthesia as per the standard practice( 25mL for posterior knee infiltration, 5mL for LFCN, 25mL for adductor canal under the fasica lata, 5ML for intermediate cutaneous nerve of thigh) and continued until discharge. CADD infusion pump will deliver Ropivacaine 0.2% at a basal infusion rate of 8 mL/Hr with no patient controlled boluses.

Group 2: Intervention- Local Infiltration + Infusion Anesthetic Wound infiltration will first be completed per standard practice using 110mL of ropivacaine 300mg, ketorolc 30mg ,morphine 10mg for infiltration. After, three peri-articular catheters (inserted into the suprapatellar pouch, anterior subcutaneous cutaneous tissue, posterior to the femur) will be inserted at the end of the case followed by periarticular infusion with CADD infusion pump delivering Ropivacaine 0.2% at a basal infusion rate of 8 mL/Hr with no patient controlled boluses

All patients will receive sedation with fentanyl and midazolam titrated to effect during the initiation of spinals and MSNB blocks. All patients will receive intravenous sedation with an infusion of a mixture of propofol and ketamine titrated to effect during surgery. Patients will be discharged home following removal of the anaesthetic catheters and fulfilling criteria for discharge

All patients will receive standard multimodal analgesia pre- and post-operatively.

Pain scores, nausea/sedation, narcotic consumption, and any post-operative complications will be assessed and documented 6 hours post-op on the day of surgery. After this, pain scores will be documented twice daily till the end of pian study period (post-discharge day 4 and once more at 2 weeks post-op) and will be recored when at rest and with mobility (two VAS scores each assessment) . Nausea and sedation will be documented at time of assessment from the patient or nursing charts as well as the patient pain diary.

The discharge criteria is as follows

  1. The patient should be able to take care of personal care, get in and out of bed, into and up from a chair, on and off a toilet and to walk with proper walking aids 70 m without time limit; ability to do five steps.
  2. Free of medical or surgical complications including urinary catheterization or need for blood transfusion
  3. Acceptable pain relief (NRS = 5/10) without any need for intravenous analgesics.
  4. No nausea/ vomiting; generalized weakness or dizziness.
  5. Knee flexion of 90 degreeed is optional but preferred.

The patients will be assessed at 6 hours of arrival to PACU and at 9 AM and 2pm on POD 1. If the patients were not discharged on POD 1 , the readiness for discharge will be at 9 AM on postoperative day 2 subsequently. WOMAC scores, KSS scores and SF-12 will be collected at the Pre-admit clinic and will be repeated at 6 weeks and three months postoperatively. Block performance characteristics prospectively collected will include procedural time, success, number of attempts and complications such as persistent paresthesia and intravascular injection. Inpatient assessment by the research team as well as a pain diary for documentation following discharge will be used to collect data including numeric pain score on movement and rest at various time intervals (twice daily), the predominant site of pain, frequency of rescue analgesic consumption, total analgesic consumption, symptoms of sedation and nausea for up to 4 days post-discharge. Time to first physiotherapy session and their progress/ability to perform rehabilitation exercises daily will be documented. Regardless of the group the patient is randomized to, their anesthetic device (MSNB or LIA infusion) will be discontinued and removed in hospital prior to discharge. Time to discharge readiness and actual duration of hospital stay will be documented.

Total patient involvement time is 3 months (from surgery to 3 month follow-up appointment).

In hospital, adverse events will be retrieved from patient charts and nursing/physician documentation. Post discharge adverse events will be collected by the patient diary and at their 2 weeks, 6 week and 3 month post-operative follow-up. These will include occurrence of myocardial events, DVT, Pulmonary emboli, delirium, pneumonia, paralytic ileus, gastrointestinal bleed, new onset renal dysfunction and wound infection.

Delayed or post- discharge adverse events and duration of narcotic therapy will be collected in the out-patient clinic at 2 weeks and at 6 weeks and 3 months after surgery at their follow-up appointment.

Wound and prosthetic infections and the presence of chronic post-surgical pain will be recorded from the surgical follow up notes.

Primary hypothesis (null):

The post-operative inpatient stay and discharge rates following TKJA are comparable between motor sparing knee blocks and peri-articular wound catheters.

Secondary hypotheses (null):

  1. Pain scores and analgesic consumption with motor sparing block or by peri-articular wound catheters are comparable.
  2. Adverse events and complication rates are comparable between the two groups.
Being tested
Motor Sparing Nerve Block, Peri-articular Catheters
Keywords
arthroplasty, wound, catheter, local, anesthesia, infiltration, Total Knee Arthroplasty
Medical subject headings
Wounds and Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Motor Sparing Nerve BlockProcedure or surgery

    Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.

  • Peri-articular CathetersProcedure or surgery

    3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.

Study groups in NCT01503528
Study groupRoleWhat they receive
Motor Sparing Nerve BlockActive comparatorMotor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
Receives: Procedure: Motor Sparing Nerve Block
Peri-Articular CathetersExperimental3 peri-articular catheters inserted at the end of surgery followed by peri-articular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
Receives: Procedure: Peri-articular Catheters

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary outcome - Perioperative pain

    Postoperative pain levels on a visual analogue scale will be recorded while the patient is an inpatient up to a maximum of 4 days post-discharge, and again at 2 weeks post-op.

    Measured: day of surgery to 2 weeks post-op

Secondary outcomes (8)
  1. Readiness and True Discharge times

    Readiness for discharge and the actual time of discharge will be recorded

    Measured: in-patient period

  2. Postoperative mobility/function

    Postoperative mobility will be assessed by a physiotherapist, and recorded using inpatient assessment notes and patient recorded physiotherapy progression following discharge in their pain diary.

    Measured: Measured on day of surgery to discharge day 4. Functional outcomes will be collected at 6 weeks and 3 months post-op using WOMAC and KSS scores

  3. Analgesia/Narcotic Consumption

    Break-through/rescue analgesia and narcotics that were consumed between assessment intervals will be documented

    Measured: day of surgery to post-discharge day 4

  4. Complications

    Post-operative complications such as myocardial events, DVT, Pulmonary emboli, delirium, pneumonia, paralytic ileus, gastrointestinal bleed, new onset renal dysfunction and wound infection

    Measured: day of surgery to 3 months post-op

  5. Nausea and Sedation symptoms

    Analgesic side-effects will be monitored and compared to narcotic consumption

    Measured: day of surgery to post-discharge day 4

  6. Patient reported pain, stiffness and functional disability.

    These variables will be assesed using the Knee Society Score and Western Ontario and McMaster Universities Arthritis Index (WOMAC score).

    Measured: Assessed preoperatively, and at 6 weeks and 3 months postoperative.

  7. Short-From Survey-12

    Overall assessment of patient's health

    Measured: Assessed preoperatively, and at 6 weeks and 3 months postoperative.

  8. Anaesthetic Procedure Performance Data

    Block performance characteristics prospectively collected will include procedural time, success, number of attempts and complications such as persistent paresthesia and intravascular injection

    Measured: peri-operatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jan 2012 (estimated)
  2. Study start16 Oct 2017
  3. Primary completion10 Sep 2018
  4. Study completion10 Sep 2018

Why it stopped: Shortage of required study drug.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a prospective randomized clinical trial. For safety and logistical reasons, it cannot be blinded. In the perioperative period multiple factors contribute to discharge readiness. The major impediments to early discharge include poor pain control, opioid related adverse events, surgical/ medical complications, inability to achieve physiotherapy end points and patient's unwillingness to be discharged. We want to compare head to head, two previously evaluated fast-track paradigms. We are not comparing just the analgesic technique alone. We are comparing the pathways where the analgesic regimes are a component and differ, keeping the common factors similar between the groups. If a technique does not allow early ambulation, patients cannot be ready for discharge and thus resource utilization will be affected.
Masking
None (open label)
Enrolment
54 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01503528
Sponsor's protocol ID
18448
Other IDs
101754
Status last verified
Feb 2019
First submitted
2 Jan 2012
Last updated
1 Mar 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Motor Sparing Nerve Block and Peri-articular Catheters in people with Knee Joint Arthritis and Knee Joint Arthroplasty, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: Shortage of required study drug.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary outcome - Perioperative pain (time frame: day of surgery to 2 weeks post-op). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2019; AzTrials last refreshed its copy on 1 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in